14 years of historical data (2011–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Theravance Biopharma, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $925M | $460M | $622M | $826M | $768M | $1.1B | $1.4B | $1.4B | $1.5B | $1.4B | $560M |
| Enterprise Value | $937M | $472M | $631M | $580M | $1.3B | $1.7B | $1.9B | $1.5B | $1.6B | $1.3B | $447M |
| P/E Ratio → | -15.87 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 14.36 | 7.14 | 10.82 | 16.08 | 13.88 | 15.42 | 19.61 | 22.88 | 94.90 | 29.30 | 13.29 |
| P/B Ratio | 5.08 | 2.62 | 2.92 | 1.87 | — | — | — | — | 12.68 | 4.07 | 2.30 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 7.33 | 10.99 | 11.29 | 24.36 | 23.70 | 25.77 | 24.14 | 103.66 | 26.79 | 10.61 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Theravance Biopharma, Inc. earns an operating margin of -72.9%. Operating margins have expanded from -179.1% to -72.9% over the past 3 years, signaling improving operational efficiency. A negative ROE of -29.0% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 29.3% | -23.5% | -250.1% | 100.0% | 100.0% | 98.8% | 60.8% | 94.1% | 88.9% |
| Operating Margin | -72.9% | -72.9% | -97.6% | -179.1% | -466.1% | -414.2% | -343.1% | -395.5% | -1690.6% | -371.0% | -431.8% |
| Net Profit Margin | -87.6% | -87.6% | -96.1% | 1698.5% | -360.6% | -386.9% | -322.1% | -357.0% | -1855.0% | -391.9% | -432.6% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -29.0% | -29.0% | -16.9% | 1689.7% | — | — | — | -677.9% | -122.6% | -64.3% | -68.4% |
| ROA | -15.3% | -15.3% | -11.2% | 177.6% | -47.3% | -63.3% | -48.8% | -43.0% | -52.8% | -40.6% | -57.1% |
| ROIC | -17.2% | -17.2% | -20.1% | -31.6% | -72.7% | -85.9% | -149.1% | -130.4% | -81.6% | -75.5% | -82.4% |
| ROCE | -13.8% | -13.8% | -12.0% | -20.6% | -77.9% | -92.6% | -66.4% | -56.8% | -53.7% | -42.9% | -66.5% |
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $12M ($50M total debt minus $38M cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.28 | 0.28 | 0.23 | 0.12 | — | — | — | — | 1.94 | 0.64 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.07 | 0.05 | -0.56 | — | — | — | — | 1.17 | -0.35 | -0.46 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -18.44 | -18.44 | -23.84 | -14.44 | -30.16 | -34.82 | -7.91 | -22.78 | -30.43 | -128.54 | — |
Short-term solvency ratios and asset-utilisation metrics
Theravance Biopharma, Inc.'s current ratio of 5.02x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 12.31x to 5.02x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.02 | 5.02 | 5.39 | 12.31 | 4.26 | 3.18 | 3.03 | 5.41 | 6.05 | 10.73 | 4.80 |
| Quick Ratio | 5.02 | 5.02 | 5.39 | 12.31 | 4.26 | 3.18 | 3.03 | 5.41 | 5.79 | 10.48 | 4.60 |
| Cash Ratio | 2.75 | 2.75 | 4.14 | 11.40 | 2.96 | 2.37 | 2.51 | 5.13 | 5.57 | 10.17 | 3.49 |
| Asset Turnover | — | 0.18 | 0.15 | 0.08 | 0.15 | 0.15 | 0.18 | 0.11 | 0.03 | 0.08 | 0.14 |
| Inventory Turnover | — | — | — | — | — | — | — | — | 0.36 | 0.24 | 0.47 |
| Days Sales Outstanding | — | 388.01 | 111.07 | 119.32 | 380.10 | 353.88 | 251.42 | 64.53 | 222.09 | 72.94 | 321.92 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Theravance Biopharma, Inc. returns 0.3% to shareholders annually primarily through share buybacks.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.3% | 0.7% | 32.1% | 16.0% | 1.2% | 0.9% | 0.2% | 0.7% | 0.6% | 0.3% | 0.1% |
| Total Shareholder Yield | 0.3% | 0.7% | 32.1% | 16.0% | 1.2% | 0.9% | 0.2% | 0.7% | 0.6% | 0.3% | 0.1% |
| Shares Outstanding | — | $49M | $55M | $74M | $69M | $62M | $56M | $54M | $52M | $45M | $34M |
Compare TBPH with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| TBPHYou | $925M | -15.9 | — | — | 100.0% | -72.9% | -29.0% | -17.2% | — |
| UTHR | $22B | 18.1 | 12.9 | 21.1 | 87.9% | 46.9% | 19.7% | 21.1% | — |
| ZLAB | $21B | -12.0 | — | — | 58.6% | -49.9% | -22.6% | -42.8% | — |
| AMRN | $6B | -3.5 | — | — | 35.6% | -40.2% | -15.8% | -18.7% | — |
| ALKS | $5B | 21.0 | 15.9 | 9571.4 | 86.3% | 17.2% | 14.7% | 14.9% | 0.2 |
| ADMA | $4B | 19.2 | 25.1 | 33.7 | 51.5% | 32.6% | 81.6% | 37.7% | 0.6 |
| ARQT | $3B | -207.5 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
| LQDA | $3B | -18.7 | — | — | 58.0% | -866.6% | -209.4% | -500.7% | — |
| SLGL | $3B | -241.3 | — | — | 98.0% | -104.1% | -31.4% | -41.5% | — |
| MLYS | $2B | -8.0 | — | — | — | — | -82.2% | -107.3% | — |
| ARDX | $2B | -25.2 | — | — | 90.3% | -10.1% | -36.2% | -10.8% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 14 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how TBPH stacks up against sector leader United Therapeutics Corporation.
Start ComparisonTheravance Biopharma, Inc.'s current P/E ratio is -15.9x. This places it at the 50th percentile of its historical range.
Theravance Biopharma, Inc.'s return on equity (ROE) is -29.0%. The historical average is -79.2%.
Based on historical data, Theravance Biopharma, Inc. is trading at a P/E of -15.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Theravance Biopharma, Inc. has 100.0% gross margin and -72.9% operating margin.